Reduce medication wearing off symptoms
- Trial ID
- NCT06145711
- Official Title
- A Clinical Trial of Parkinson's Disease Treatment by Human-induced Pluripotent Stem Cells (hiPSCs) Derived Dopaminergic Neural Precursor Cells
- Goal
- Reduce medication wearing off symptoms
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Shanghai East Hospital
- Study Type
- INTERVENTIONAL
- Enrollment
- 3 participants
- Conditions
- Parkinson's Disease
- Interventions
- hiPSC-DAP
Plain-Language Summary
It aims to replace the dopamine-producing cells lost in Parkinson's to reduce severe motor symptoms and the levodopa wearing-off that no longer responds well to medication. Surgeons inject dopaminergic neural precursor cells made from human-induced pluripotent stem cells into targeted brain areas using stereotactic surgery, the transplanted cells are intended to mature into dopamine neurons and supply a steadier source of dopamine, potentially lowering reliance on levodopa and smoothing motor fluctuations. Looking for adults 30 to 70 years old with primary Parkinson's for more than 5 years, mostly moderate to advanced disease (Hohen‑Yahr stage 3,4), clear and stable OFF-period motor scores, prior benefit then wearing-off on levodopa, stable meds for 3+ months, and the ability to undergo brain surgery with a caregiver to help.
Locations
- Shanghai East Hospital, Shanghai, Shanghai Municipality, China
- Shanghai East Hospital, Shanghai, Shanghai Municipality, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying hiPSC-DAP. It aims to replace the dopamine-producing cells lost in Parkinson's to reduce severe motor symptoms and the levodopa wearing-off that no longer responds well to medication. Surgeons inject dopaminergic neural precursor cells made from human-induced pluripotent stem cells into targeted brain areas using stereotactic surgery, the transplanted cells are intended to mature into dopamine neurons and supply a steadier source of dopamine, potentially lowering reliance on levodopa and smoothing motor fluctuations. Looking for adults 30 to 70 years old with primary Parkinson's for more than 5 years, mostly moderate to advanced disease (Hohen‑Yahr stage 3,4), clear and stable OFF-period motor scores, prior benefit then wearing-off on levodopa, stable meds for 3+ months, and the ability to undergo brain surgery with a caregiver to help.
- Who can participate?
- Participants must be between 30 Years and 70 Years.
- Where is this trial located?
- This trial is recruiting at 2 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 1 month.